Deep within the world's oceans lurk marine bacteria armed with plastic-munching enzymes, their evolution seemingly sculpted ...
Collaborating researchers have made a breakthrough discovery regarding the intricate defense systems of bacteriophages (phages)—viruses that can specifically target harmful bacteria without harming ...
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...
Urinary tract infections are among the most common medical conditions in women, with over 50% experiencing at least one UTI in their lifetime and about 30% suffering recurrent infections. The ...
An analysis of the bones and teeth of ancient mammoths (Mammuthus) has identified some of the microorganisms that lived in the animals’ mouths and bodies more than one million years ago. The study, ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa, GSK), a new oral antibiotic for uncomplicated urinary tract infections (UTIs) in females aged 12 years ...
Eukaryotic Polα-primase contains DNA polymerase (Pol1) and RNA primase subunits that together synthesize a >20-nucleotide hybrid RNA–DNA primer. Bacteria and archaea only require a dozen or less RNA ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were randomly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback